CRMD (Cormedix) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cormedix 3-Year Revenue Growth Rate?

Cormedix's Revenue per Share for the three months ended in Sep. 2024 was $0.20.

During the past 12 months, Cormedix's average Revenue per Share Growth Rate was 20800.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Cormedix was 210.70% per year. The lowest was -45.00% per year. And the median was -26.30% per year.

Competitive Comparison of Cormedix's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Cormedix's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cormedix's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cormedix's 3-Year Revenue Growth Rate falls into.

Cormedix 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Cormedix (NAS:CRMD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Cormedix 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cormedix's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cormedix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

19KA:Germany

Address

300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922

Website

https://www.cormedix.com

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Executives

Elizabeth Masson	officer: EVP, Head of Clinical Ops.	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Joseph Todisco	director, officer: Chief Executive Officer	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry	officer: Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Myron Kaplan	director	C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa	director	MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart	director	360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione	director	ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David	officer: EVP, Chief Financial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel	officer: EVP, Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz	director	SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan	director	700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L.	officer: Exec VP of Tech Operations	C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Phoebe Mounts	officer: General Counsel	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07822